Skye Bioscience Inc. (SKYE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMUN 
Arecor partners with Skye Bioscience to improve formulation of obesity drug
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experimental obesity treatment, as drugmakers vie for a share of the fast-growing weight-loss market. The Cambridge-based company will use its proprietary Arestat technology to reformulate nimacimab, a monoclonal antibody developed by Skye that targets the CB1 receptor.
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive Officer Chris Twitty - Chief Scientific Officer Kaitlyn Arsenault - Chief Financial Officer Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Conference Call Participants Jay Olson - Oppenheimer Albert Lowe - Craig-Hallum Ted Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Andy Hsieh - William Blair Jon Wolleben - Citizens JMP Bernie Hertel Hello, and thank you all for participating in today's call. Joining me today is Punit Dhillon, Skye's President and CEO; Chris Twitty, CSO, and Kaitlyn Arsenault, Skye's CFO.
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with significant weight loss results in mouse models, making it a speculative but potentially rewarding investment. 26-week results for the Phase 2a are expected in late Q3 or early Q4, so positive catalysts are on the horizon.
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Executive Officer Kaitlyn Arsenault - Chief Financial Officer Chris Twitty - Chief Scientific Officer Tu Diep - Chief Operating Officer Puneet Arora - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co. Edward Tenthoff - Piper Sandler & Co. Jay Olson - Oppenheimer & Co. Inc. Andy Hsieh - William Blair & Company George Farmer - Scotiabank Jonathan Wolleben - Citizens JMP Securities Albert Lowe - Craig-Hallum Capital Group Operator Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today.
Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy
Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. Nimacimab's large-molecule design avoids neuropsychiatric side effects, a major issue with earlier CB1 inhibitors like rimonabant and monlunabant. The drug's preclinical evidence suggests fat-specific weight loss, lean muscle preservation, and appetite regulation, positioning it as a competitive alternative to GLP-1 therapies.
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Bernie Hertel - Head, Investor Relations Punit Dhillon - President and CEO Kaitlyn Arsenault - Chief Financial Officer Chris Twitty - Chief Scientific Officer Dr. Puneet Arora - Chief Medical Officer Conference Call Participants Edward Tenthoff - Piper Sandler Jay Olson - Oppenheimer George Farmer - ScotiaBank Albert Lowe - Craig-Hallum Ayan Hussein - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience NASDAQ: SKYE is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO has prompted Wall Street analysts to place high expectations on Skye Bioscience.
Skye: Moving Weight Loss Drugs To The Next Level
Skye Bioscience, Inc. interim data from phase 2 CBeyond study, using nimacimab for the treatment of patients with obesity, is expected Q2 and Q4 of 2025. Experimental arm added into phase 2 CBeyond study, which is combining the use of nimacimab with Wegovy for the treatment of patients with obesity. The global obesity drugs market is expected to reach $105 billion in 2030.
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ:SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SKYE.
